A Personalized Cancer Management Vision
WWiKY’s ‘personalized care’ approach is based on hypoxia-specific imaging with a hypoxia-sensitive radiopharmaceutical which selects treatment-responsive patients. Therapeutic doses of the same radiopharmaceutical are prescribed uniquely for each patient, using that patient’s image-based pharmacokinetic and radiodosimetric profiles to ensure precise therapeutically effective dose, thereby reducing or eliminating treatment failure and minimizing toxicity. In summary, only responsive patients are treated by receiving individualized doses of our drug, thereby reducing the risk of treatment failure and minimizing negative social, health and financial risks.
WWiKY’s research, innovation and product development are based on expertise in radiopharmaceuticals, pharmaceuticals, chemical and biomolecular sciences, focusing on the development of targeted molecules based on pharmacokinetic, radiation dosimetry and nuclear medicine principles. Nuclear imaging that utilizes planar, SPECT (single photon emission computed tomography) and PET (positron emission tomography) technologies is harnessed to create cancer therapies based on cellular and molecular biology and are integrated with health care economics to offer effective, safe and precise anti cancer treatment.
Conventional drug and radiotherapy treatments are expensive and all too frequently, ineffective. WWiKY’s theranostic agents are designed to manage oxygen-deficient (hypoxic), therapy resistant cancers that are characterized by invasive metastatic potential, high patient morbidity and mortality. Hypoxic tumors contribute serious social burdens and create financial and economic stress on healthcare systems. Ineffective, non-targeted treatment regimens augment these problems through unnecessary discomfort, systemic toxicity and reduction of the patient’s quality of life and life expectancy.